Health And Pharma11d
MATTERHORN Trial: Imfinzi Shows Significant Survival Benefit in Gastric and GEJ Cancer Treatment
The Phase III MATTERHORN trial demonstrated that Imfinzi (durvalumab) plus FLOT chemotherapy significantly improved ...
Health And Pharma13d
How SkinJect's Microneedle Technology Could Transform the Treatment of Skin Cancer
Today, we are hosting Dr. Raza Bokhari, CEO at Medicus Pharma, to explore a breakthrough innovation in skin cancer ...
healthandpharma15d
FDA Approves Tislelizumab Plus Chemotherapy for PD-L1+ Metastatic Esophageal Cancer
The US FDA has approved Tislelizumab (Tevimbra) plus platinum-based chemotherapy as a first-line treatment for adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) ...
Health And Pharma15d
CHMP Recommends Durvalumab Combination for EU Approval in Resectable NSCLC
AstraZeneca announced that a durvalumab (Imfinzi)-based perioperative regimen has been recommended by the EMA Committee for ...
Health And Pharma24y
KEYTRUDA Receives Priority FDA Review for Perioperative Use in ES Head and Neck Cancer
KEYTRUDA (pembrolizumab) plus standard care for resectable locally advanced head and neck squamous cell carcinoma receives ...
healthandpharma22d
Patient Enrollment Completed in VAPOR 2 Trial for Vanquish Prostate Cancer Therapy
Francis Medical, a medical device company developing water vapor ablation therapy for the treatment of prostate, kidney, and bladder cancer, announced the completion of patient enrollment and initial ...
healthandpharma19d
Enhertu Gains EMA’s CHMP Support for HER2-Low Metastatic Breast Cancer Treatment
The European Medicines Agency (EMA) committee (CHMP) has recommended approving trastuzumab deruxtecan (Enhertu), a HER2-directed antibody-drug conjugate for certain patients with metastatic breast ...